Fc receptor-mediated immune responses: New tools but increased complexity in HIV prevention

Current HIV Research

Volumn 11, Issue 5, 2013, Pages 407-420

  Vargas Inchaustegui, Diego A ^a   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibody dependent cell mediated viral inhibition; Antibody dependent cellular cytotoxicity; Antibody dependent cellular phagocytosis; Avidity; B cell memory; Fc glycosylation; FcR polymorphisms; Transcytosis inhibition

Indexed keywords

CD16 ANTIGEN; CD32 ANTIGEN; CD64 ANTIGEN; ERDOSTEINE; FC RECEPTOR; GAMMA INTERFERON; GRANZYME B; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 2; MATRIX METALLOPROTEINASE; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CELL MATURATION; CELL PHAGOCYTOSIS; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); GENETIC POLYMORPHISM; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; MEMORY CELL; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PHENOTYPE; SEROLOGY; TRANSCYTOSIS; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; PHAGOCYTOSIS; POLYMORPHISM, GENETIC; RECEPTORS, IGG; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84889004790     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X113116660063     Document Type: Article

References (188)

1. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999; 283: 857-60.
2. Jin X, Bauer DE, Tuttleton SE, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999; 189: 991-8.
3. Prince AM, Reesink H, Pasqual D, et al. Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retroviruses 1991; 7: 971-3.
4. Emini EA, Schleif WA, Nunberg JH, et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992; 355: 728-30.
5. Shibata R, Igarashi T, Haigwood N, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999; 5: 204-10.
6. Mascola JR, Lewis MG, Stiegler G, et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89. 6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73: 4009-18.
7. Baba TW, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6: 200-6.
8. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6: 207-10.
9. Parren PW, Marx PA, Hessell AJ, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75: 8340-7.
10. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 2012; 54: 1615-7.
11. Bomsel M, Heyman M, Hocini H, et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 1998; 9: 277-87.
12. Huber M, Trkola A. Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 2007; 262: 2-25.
13. Lyerly HK, Reed DL, Matthews TJ, et al. Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. AIDS Res Hum Retroviruses 1987; 3: 409-22.
14. Koup RA, Sullivan JL, Levine PH, et al. Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J Virol 1989; 63: 584-90.
15. Koup RA, Pikora CA, Mazzara G, Panicali D, Sullivan JL. Broadly reactive antibody-dependent cellular cytotoxic response to HIV-1 envelope glycoproteins precedes broad neutralizing response in human infection. Viral Immunol 1991; 4: 215-23.
16. Baum LL, Cassutt KJ, Knigge K, et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 1996; 157: 2168-73.
17. Banks ND, Kinsey N, Clements J, Hildreth JE. Sustained antibodydependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res Hum Retroviruses 2002; 18: 1197-205.
18. Ojo-Amaize E, Nishanian PG, Heitjan DF, et al. Serum and effector-cell antibody-dependent cellular cytotoxicity (ADCC) activity remains high during human immunodeficiency virus (HIV) disease progression. J Clin Immunol 1989; 9: 454-61.
19. Dalgleish A, Sinclair A, Steel M, Beatson D, Ludlam C, Habeshaw J. Failure of ADCC to predict HIV-associated disease progression or outcome in a haemophiliac cohort. Clin Exp Immunol 1990; 81: 5-10.
20. Tyler DS, Stanley SD, Nastala CA, et al. Alterations in antibodydependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J Immunol 1990; 144: 3375-84.
21. Ahmad A, Morisset R, Thomas R, Menezes J. Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIV-infected individuals. J Acquir Immune Defic Syndr 1994; 7: 428-37.
22. Gómez-Román VR, Patterson LJ, Venzon D, et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005; 174: 2185-9.
23. Gómez-Román VR, Florese RH, Patterson LJ, et al. A simplified method for the rapid fluorometric assessment of antibodydependent cell-mediated cytotoxicity. J Immunol Methods 2006; 308: 53-67.
24. Pollara J, Hart L, Brewer F, et al. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 2011; 79: 603-12.
25. Smalls-Mantey A, Doria-Rose N, Klein R, et al. Antibodydependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J Virol 2012; 86: 8672-80.
26. Migueles SA, Osborne CM, Royce C, et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008; 29: 1009-21.
27. Stratov I, Chung A, Kent SJ. Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol 2008; 82: 5450-9.
28. Alpert MD, Harvey JD, Lauer WA, et al. ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog 2012; 8: e1002890.
29. Hidajat R, Xiao P, Zhou Q, et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol 2009; 83: 791-801.
30. Florese RH, Demberg T, Xiao P, et al. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol 2009; 182: 3718-27.
31. Xiao P, Zhao J, Patterson LJ, et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89. 6P challenge in rhesus macaques. J Virol 2010; 84: 7161-73.
32. Xiao P, Patterson LJ, Kuate S, et al. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. J Virol 2012; 86: 4644-57.
33. Wren LH, Chung AW, Isitman G, et al. Specific antibodydependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology 2013; 138: 116-23.
34. Chung AW, Isitman G, Navis M, et al. Immune escape from HIVspecific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci USA 2011; 108: 7505-10.
35. Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J. HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog 2012; 8: e1002739.
36. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366: 1275-86.
37. Karnasuta C, Paris RM, Cox JH, et al. Antibody-dependent cellmediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 2005; 23: 2522-9.
38. Montefiori DC, Karnasuta C, Huang Y, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 2012; 206: 431-41.
39. Florese RH, Van Rompay KK, Aldrich K, et al. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol 2006; 177: 4028-36.
40. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449: 101-4.
41. Yamada T, Watanabe N, Nakamura T, Iwamoto A. Antibodydependent cellular cytotoxicity via humoral immune epitope of Nef protein expressed on cell surface. J Immunol 2004; 172: 2401-6.
42. Isitman G, Chung AW, Navis M, Kent SJ, Stratov I. Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology 2011; 412: 110-6.
43. Gómez-Román VR, Florese RH, Peng B, et al. An adenovirusbased HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. J Acquir Immune Defic Syndr 2006; 43: 270-7.
44. Ferrari G, Pollara J, Kozink D, et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 2011; 85: 7029-36.
45. Bonsignori M, Pollara J, Moody MA, et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 2012; 86: 11521-32.
46. Finnegan CM, Berg W, Lewis GK, DeVico AL. Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion. J Virol 2001; 75: 11096-105.
47. DeVico AL. CD4-induced epitopes in the HIV envelope glycoprotein, gp120. Curr HIV Res 2007; 5: 561-71.
48. Guan Y, Pazgier M, Sajadi MM, et al. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci USA 2013; 110: E69-78.
49. Forthal DN, Landucci G. In vitro reduction of virus infectivity by antibody-dependent cell-mediated immunity. J Immunol Methods 1998; 220: 129-38.
50. + lymphocyte count. AIDS Res Hum Retroviruses 2001; 17: 553-61.
51. Van Rompay KKA, Verardi CJ, Dillard-Telm S, et al. Passive Immunization of Newborn Rhesus Macaques Prevents Oral Simian Immunodeficiency Virus Infection. J Infect Dis 1998; 177: 1247-59.
52. Forthal DN, Landucci G, Cole KS, Marthas M, Becerra JC, Van Rompay K. Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J Virol 2006; 80: 9217-25.
53. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005; 191: 666-77.
54. Forthal DN, Gilbert PB Landucci G, Phan T. Recombinant gp120 Vaccine-Induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007; 178: 6596-603.
55. Bialuk I, Whitney S, Andresen V, et al. Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques. Vaccine 2011; 30: 78-94.
56. Asmal M, Sun Y, Lane S, et al. Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses. J Virol 2011; 85: 5465-75.
57. Sun Y, Asmal M, Lane S, et al. Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. J Virol 2011; 85: 6906-12.
58. Ackerman ME, Moldt B, Wyatt RT, et al. A robust, highthroughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods 2011; 366: 8-19.
59. Mela CM, Steel A, Lindsay J, Gazzard BG, Gotch FM, Goodier MR. Depletion of natural killer cells in the colonic lamina propria of viraemic HIV-1-infected individuals. AIDS 2007; 21: 2177-82.
60. Sips M, Sciaranghella G, Diefenbach T, et al. Altered distribution of mucosal NK cells during HIV infection. Mucosal Immunol 2012; 5: 30-40.
61. Holl V, Peressin M, Moog C. Antibody-mediated Fcγ receptorbased mechanisms of HIV inhibition: recent findings and new vaccination strategies. Viruses 2009; 1: 1265-94.
62. Ackerman ME, Dugast AS, McAndrew EG, et al. Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b. J Virol 2013; 87(10): 5468-76.
63. Perez LG, Zolla-Pazner S, Montefiori DC. Antibody-dependent, FcγRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis. J Virol 2013; 87: 5287-90.
64. Huber M, von Wyl V, Ammann CG, et al. Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked. J Virol 2008; 82: 3834-42.
65. Holl V, Peressin M, Schmidt S, et al. Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation. Blood 2006; 107: 4466-74.
66. Holl V, Peressin M, Decoville T, et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006; 80: 6177-81.
67. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med 1997; 3: 42-7.
68. Kochut A, Dersch P. Bacterial invasion factors: Tools for crossing biological barriers and drug delivery? Eur J Pharm Biopharm 2012; 84(2): 242-50.
69. Nikitas G, Deschamps C, Disson O, Niault T, Cossart P, Lecuit M. Transcytosis of Listeria monocytogenes across the intestinal barrier upon specific targeting of goblet cell accessible E-cadherin. J Exp Med 2011; 208: 2263-77.
70. Martin-Latil S, Gnadig NF, Mallet A, et al. Transcytosis of HTLV-1 across a tight human epithelial barrier and infection of subepithelial dendritic cells. Blood 2012; 120: 572-80.
71. Denton PW, Garcia JV. Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. Trends Microbiol 2012; 20: 268-74.
72. Tebit DM, Ndembi N, Weinberg A, et al. Mucosal transmission of human immunodeficiency virus. Curr HIV Res 2012; 10: 3-8.
73. Fagarasan S, Honjo T. Intestinal IgA synthesis: regulation of frontline body defences. Nat Rev Immunol 2003; 3: 63-72.
74. Macpherson AJ, Slack E. The functional interactions of commensal bacteria with intestinal secretory IgA. Curr Opin Gastroenterol 2007; 23: 673-8.
75. Jain S, Rosenthal KL. The gp41 epitope, QARVLAVERY, is highly conserved and a potent inducer of IgA that neutralizes HIV-1 and inhibits viral transcytosis. Mucosal Immunol 2011; 4: 539-53.
76. Devito C, Broliden K, Kaul R, et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 2000; 165: 5170-6.
77. Mestecky J, Moldoveanu Z, Smith PD, Hel Z, Alexander RC. Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection. J Reprod Immunol 2009; 83: 196-200.
78. Bomsel M, Heyman M, Hocini H, et al. intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 1998; 9: 277-87.
79. Hocini H, Belec L, Iscaki S, et al. High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160. AIDS Res Human Retroviruses 1997; 13: 1179-85.
80. Hocini H, BomselM. Infectious human immunodeficiency virus can rapidly penetrate a tight human epithelial barrier by transcytosis in a process impaired by mucosal immunoglobulins. J Infect Dis 1999; 179 S3: S448-53.
81. Bomsel M, Tudor D, Drillet AS, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011; 34: 269-80.
82. Leroux-Roels G, Maes C, Clement F, et al. Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes. PLoS One 2013; 8: e55438.
83. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331: 44-9.
84. Di Santo JP. Functionally distinct NK-cell subsets: developmental origins and biological implications. Eur J Immunol 2008; 38: 2948-51.
85. Cooper MA, Fehniger TA, Caliguri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633-40.
86. Yokoyama WM, Plougastel BF. Immune functions encoded by the natural killer gene complex. Nat Rev Immunol 2003; 3: 304-16.
87. Bryceson YT, Long EO. Line of attack: NK cell specificity and integration of signals. Curr Opin Immunol 2008; 20: 344-52.
88. Webster RL, Johnson RP. Delineation of multiple subpopulations of natural killer cells in rhesus macaques. Immunology 2005; 115: 206-14.
89. Reeves RK, Gillis J, Wong FE, Yu Y, Connole M, Johnson RP. CD16-natural killer cells: enrichment in mucosal and secondary lymphoid tissues and altered function during chronic SIV infection. Blood 2010; 115: 4439-46.
90. Vargas-Inchaustegui DA, Xiao P, Tuero I, Patterson LJ, Robert-Guroff M. NK and CD4+ T cell cooperative immune responses correlate with control of disease in a macaque simian immunodeficiency virus infection model. J Immunol 2012; 189: 1878-85.
91. Vargas-Inchaustegui DA, Demberg T, Robert-Guroff M. A CD8alpha(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibodyindependent cytotoxic activities. Immunology 2011; 134: 326-40.
92. Reeves RK, Rajakumar PA, Evans TI, et al. Gut inflammation and indoleamine deoxygenase inhibit IL-17 production and promote cytotoxic potential in NKp44+ mucosal NK cells during SIV infection. Blood 2011; 118: 3321-30.
93. Hughes T, Becknell B, McClory S, et al. Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH17 cytokine interleukin-22. Blood 2009; 113: 4008-10.
94. Crellin NK, Trifari S, Kaplan CD, Cupedo T, Spits H. Human NKp44+IL-22+ cells and LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells. J Exp Med 2010; 207: 281-90.
95. Hong HS, Rajakumar PA, Billingsley JM, Reeves RK, Johnson RP. No monkey business: why studying NK cells in non-human primates pays off. Front Immunol 2013; 4: 32.
96. Boulet S, Kleyman M, Kim JY, et al. A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. AIDS 2008; 22: 1487-91.
97. Chung A, Rollman E, Johansson S, Kent SJ, Stratov I. The utility of ADCC responses in HIV infection. Curr HIV Res 2008; 6: 515-9.
98. Chung AW, Rollman E, Center RJ, Kent SJ, Stratov I. Rapid degranulation of NK cells following activation by HIV-specific antibodies. J Immunol 2009; 182: 1202-10.
99. Lichtfuss GF, Meehan AC, Cheng WJ, et al. HIV inhibits early signal transduction events triggered by CD16 cross-linking on NK cells, which are important for antibody-dependent cellular cytotoxicity. J Leuk Biol 2011; 89: 149-58.
100. Min-Oo G, Kamimura Y, Hendricks DW, Nabekura T, Lanier LL. Natural killer cells: walking three paths down memory lane. Trends Immunol 2013; 34(6): 251-8.
101. Paust S, von Andrian UH. Natural killer cell memory. Nat Immunol 2011; 12: 500-8.
102. Sun JC, Lanier LL. Versatility in NK cell memory. Immunol Cell Biol 2011; 89: 327-9.
103. Cooper MA, Colonna M, Yokoyama WM. Hidden talents of natural killers: NK cells in innate and adaptive immunity. EMBO Rep 2009; 10: 1103-10.
104. Fehniger TA, Cooper MA, Nuovo GJ, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003; 101: 3052-7.
105. He XS, Draghi M, Mahmood K, et al. T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus. J Clin Invest 2004; 114: 1812-9.
106. McCall MB, Roestenberg M, Ploemen I, et al. Memory-like IFNgamma response by NK cells following malaria infection reveals the crucial role of T cells in NK cell activation by P. falciparum. Eur J Immunol 2010; 40: 3472-7.
107. Horowitz A, Behrens RH, Okell L, Fooks AR, Riley EM. NK cells as effectors of acquired immune responses: effector CD4+ T celldependent activation of NK cells following vaccination. J Immunol 2010; 185: 2808-18.
108. Horowitz A, Newman KC, Evans JH, Korbel DS, Davis DM, Riley EM. Cross-talk between T cells and NK cells generates rapid effector responses to Plasmodium falciparum-infected erythrocytes. J Immunol 2010; 184: 6043-52.
109. Vantourout P, Hayday A. Six-of-the-best: unique contributions of γδ T cells to immunology. Nat Rev Immunol 2013; 13: 88-100.
110. Harris LD, Klatt NR, Vinton C, et al. Mechanisms underlying γδ Tcell subset perturbations in SIV-infected Asian rhesus macaques. Blood 2010; 116: 4148-57.
111. Urban EM, Chapoval AI, Pauza CD. Repertoire development and the control of cytotoxic/effector function in human γδ T cells. Clin Dev Immunol 2010; 2010: 732893.
112. Riedel DJ, Safadi MM, Armstrong CL, et al. Natural viral suppressors of HIV-1 have a unique capacity to maintain γδ T cells. AIDS 2009; 23: 1955-64.
113. Agrati C, D'Offizi G, Gougeon ML. Innate gamma/delta T-cells during HIV infection: terra relatively incognita in novel vaccination strategies? AIDS Rev 2011; 13: 3-12.
114. Angelini DF, Borsellino G, Poupot M, et al. FcγRIII discriminates between 2 subsets of Vγ9Vδ2 effector cells with different responses and activation pathways. Blood 2004; 104: 1801-7.
115. Lafont V, Liautard J, Liautard JP, Favero J. Production of TNF-α by human Vγ9Vδ2 T cells via engagement of FcγRIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen. J Immunol 2001; 166: 7190-9.
116. Poonia B, Pauza CD. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity. Cytotherapy 2012; 14: 173-81.
117. Couzi L, Pitard V, Sicard X, et al. Antibody-dependent anticytomegalovirus activity of human γδ T cells expressing CD16 (FcγRIIIa). Blood 2012; 119: 1418-27.
118. Wu Y, Wu W, Wong WM, et al. Human gamma delta T cells: a lymphoid lineage cell capable of professional phagocytosis. J Immunol 2009; 183: 5622-9.
119. Nimmerjahn F, Ravetch JV. Fc-receptors as regulators of immunity. Adv Immunol 2007; 96: 179-204.
120. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol 2008; 8: 34-47.
121. Siberil S, Dutertre C-A, Fridman W-H, Teillaud J-L. FcγR: the key to optimize therapeutic antibodies? Crit Rev Oncol Hematol 2007; 62: 26-33.
122. Wines BD, Hogarth PM. IgA receptors in health and disease. Tissue Antigens 2006; 68: 103-14.
123. Woof JM, Kerr MA. The function of immunoglobulin A in immunity. J Pathol 2006; 208: 270-82.
124. van Sorge NM, van der Pol W-L, van de Winkel JGJ. FcγR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003; 61: 189-202.
125. Brouwer KC, Lal AA, Mirel LB, et al. Polymorphism of Fc receptor IIa for immunoglobulin G is associated with placental malaria in HIV-1-positive women in western Kenya. J Infect Dis 2004; 190: 1192-8.
126. Meletiadis J, Walsh TJ, Choi EH, et al. Study of common functional genetic polymorphisms of FCGR2A, 3A and 3B genes and the risk for cryptococcosis in HIV-uninfected patients. Med Mycol 2007; 45: 513-8.
127. Lehrnbecher T, Foster CB, Zhu S, et al. Variant genotypes of FcγRIIIA influence the development of Kaposi's sarcoma in HIVinfected men. Blood 2000; 95: 2386-90.
128. Brouwer KC, Lal RB, Mirel LB, et al. Polymorphism of Fc receptor IIa for IgG in infants is associated with susceptibility to perinatal HIV-1 infection. AIDS 2004; 18: 1187-94.
129. Forthal DN, Landucci G, Bream J, Jacobson LP, Phan TB, Montoya B. FcγRIIa genotype predicts progression of HIV infection. J Immunol 2007; 179: 7916-23.
130. Poonia B, Kijak GH, Pauza CD. High affinity allele for the gene of FCGR3A is risk factor for HIV infection and progression. PLoS One 2010; 5: e15562.
131. Forthal DN, Gabriel EE, Wang A, Landucci G, Phan TB. Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood 2012; 120: 2836-42.
132. Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 2003; 13: 387-98.
133. Bakema JE, van Egmond M. The human immunoglobulin A Fc receptor FcγRI: a multifaceted regulator of mucosal immunity. Mucosal Immunol 2011; 4: 612-24.
134. Robinson JK, Blanchard TG, Levine AD, Emancipator SN, Lamm ME. A mucosal IgA-mediated excretory immune system in vivo. J Immunol 2001; 166: 3688-92.
135. Van Egmond M, van Garderen E, van Spriel AV, et al. FcγRIpositive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity. Nat Med 2000; 6: 680-5.
136. Mota G, Manciulea M, Cosma E, et al. Human NK cells express Fc receptors for IgA which mediate signal transduction and target cell killing. Eur J Immunol 2003; 33: 2197-205.
137. Kitamura T, Garofalo RP, Kamijo A, et al. Human intestinal epithelial cells express a novel receptor for IgA. J Immunol 2000; 164: 5029-34.
138. Lamkhioued B, Gounni AS, Gruart V, Pierce A, Capron A, Capron M. Human eosinophils express a receptor for secretory component: role in secretory IgA-dependent activation. Eur J Immunol 1995; 25: 117.
139. Heystek HC, Moulon C, Woltman AM, Garonne P, and van Kooten C. Human immature dendritic cells efficiently bind and take up secretory IgA without the induction of maturation. J Immunol 2002; 168: 102-7.
140. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25: 21-50.
141. Okazaki A, Shoji-Hosaka E, Nakamura K, et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcγRIIIa. J Mol Biol 2004; 336: 1239-49.
142. Ferrara C, Stuart F, Sondermann P, Brunker P, Umana P. The carbohydrate at FcγRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 2006 281: 5032-6.
143. 2-linked oligosaccharides. J Immunol Methods 2005; 306: 151-60.
144. Peipp M, van Bueren JJL, Schneider-Merck T, et al. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 2008; 112: 2390-9.
145. Forthal DN, Gach JS, Landucci G, et al. Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J Immunol 2010; 185: 6876-82.
146. Moldt B, Shibata-Koyama M, Rakasz EG, et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol 2012; 86: 6189-96.
147. Ackerman ME, Crispin M, Yu X, et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest 2013; 123(5): 2183-92.
148. Nguyen DC, Scinicariello F, Attanasio R. Characterization and allelic polymorphisms of rhesus macaque (Macaca mulatta) IgG Fc receptor genes. Immunogenetics 2011; 63(6): 351-62.
149. Rogers KA, Scinicariello F, Attanasio R. IgG Fc receptor III homologues in nonhuman primate species: genetic characterization and ligand interactions. J Immunol 2006; 177(6): 3848-56.
150. Miller CJ, Genesca M, Abel K, et al. Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. J Virol 2007; 81: 5024-35.
151. Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol 2013; 31: 705-42.
152. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361: 2209-20.
153. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9: 235-45.
154. DeMilito A. B lymphocyte dysfinctions in HIV infection. Curr HIV Res 2004; 2: 11-21.
155. Yoon V, fridkis-Hareli M, Munisamy S, Lee J, Anastasiades D, Stevceva L. The gp120 molecule of HIV-1 and its interaction with T cells. Curr Med Chem 2010; 17: 741-9.
156. Lanzavecchia A, Sallusto F. Human B cell memory. Curr Opin Immunol 2009; 21: 298-304.
157. Moir S, Ho J, Malaspina A, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med 2008; 205: 1797-805.
158. Titanji K, Velu v, Chennareddi L, et al. Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infectd macaques. J Clin Invest 2010; 120: 3878-90.
159. Demberg T, Brocca-Cofano E, Xiao P, et al. Dynamics of memory B-cell populations in blood, lymph nodes, and bone marrow during antiretroviral therapy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques. J Virol 2012; 86: 12591-604.
160. Brocca-Cofano E, McKinnon K, Demberg T, et al. Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. Vaccine 2011; 29: 3310-19.
161. Sundling C, Martinez P, Soldemo M, et al. Immunization of macaques with soluble HIV type 1 and influenza virus envelope glycoproteins results in a similarly rapid contraction of peripheral B-cell responses after boosting. J Infect Dis 2013; 207: 426-31.
162. Peruchon S, Chaoul N, Burelout C, et al. tissue-specific B-cell dysfunction and generalized memory B-cell loss during acute SIV infection. PLos One 2009; 4: e5966.
163. Das A, Veazey RS, Wang X, Lackner AA, Xu H, Pahar B. Simian immunodeficiency virus infection in rhesus macaques induces selective tissue specific B cell defects in double positive CD21+CD27+ memory B cells. Clin Immunol 2011; 140: 223-8.
164. Siegrist CA, Pihlgren M, Tougne C, et al. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 2004; 23: 615-22.
165. Cole KS, Rowles JL, Jagerski BA, et al. Evolution of envelopespecific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J Virol 1997; 71: 5069-79.
166. Hammond SA, Raabe ML, Issel CJ, Montelaro RC. Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus. Virology 1999; 262: 416-430.
167. Barnett SW, Burke B, Sun Y, et al. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J Virol 2010; 84: 5975-85.
168. Lai L, Kwa S, Kozlowski PA, et al. Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis 2011; 204: 164-73.
169. Zhao J, Lai L, Amara RR, et al. Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. J Virol 2009; 83: 4102-11.
170. Pegu P, Vaccari M, Gordon S, et al. Antibodies with high avidity to the gp120 envelope protein in protection from SIVmac251 acquisition in an immunization regimen that mimics the RV-144 Thai Trial. J Virol 2012; 87: 1708-19.
171. Dey AK, Srivastava IK. Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens. Expert Rev Vaccines 2011; 10: 227-51.
172. Loré K, Karlsson Hedestam GB. Novel adjuvants for B cell immune responses. Curr Opin HIV AIDS 2009; 4: 441-6.
173. Re MC, Bon I, Grandi N, et al. Recent and long-lasting infections: the need for avidity testing in HIV-1 infected subjects. New Microbiol 2012; 35: 407-14.
174. Liao HX, Bonsignori M, Alam SM, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 2013; 38: 176-86.
175. Broliden PA, Ljunggren K, Hinkula J, Norrby E, Akerblom L, Wahren B. A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization. J Virol 1990; 64: 936-40.
176. Forthal DN, Landucci G, Phan TB, Becerra J. Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1. J Virol 2005; 79: 2042-9.
177. Burton DR, Hessell AJ, Keele BF, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA 2011; 108: 11181-6.
178. Hessell AJ, Rakasz EG, Poignard P, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Path 2009; 5: e1000433.
179. Alpert MD, Heyer LN, Williams DEJ, et al. A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1-or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays. J Virol 2012; 86: 12039-52.
180. Lambotte O, Ferrari G, Moog C, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009; 23: 897-906.
181. Bender BS, Davidson BL, Kline R, Brown C, Quinn TC. Role of the mononuclear phagocyte system in the immunopathogenesis of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Rev Infect Dis 1988; 10: 1142-54.
182. Tyler DS, Stanley SD, Nastala CA, et al. Alterations in antibodydependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J Immunol 1990; 144: 3375-84.
183. Thomas CA, Weinberger OK, Ziegler BL, et al. Human immunodeficiency virus-1 env impairs Fcγ receptor-mediated phagocytosis via a cyclic adenosine monophosphate-dependent mechanism. Blood 1997; 90: 3760-5.
184. Dugast A-S, Tonelli A, Berger CT, et al. Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. Virology 2011; 415: 160-7.
185. Liu Q, Sun Y, Rihn S, et al. Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection. J Virol 2009; 83: 8705-12.
186. Brunetta E, Hudspeth KL, Mavilio D. Pathologic natural killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes. J Leuk Biol 2010; 88: 1119-30.
187. Lichtfuss GF, Meehan AC, Cheng W-J, et al. HIV inhibits early signal transduction events triggered by CD16 cross-linking on NK cells, which are important for antibody-dependent cellular cytotoxicity. J Leuk Biol 2011; 89: 149-58.
188. He X, Li D, Luo Z, et al. Compromised NK cell-mediated antibody-dependent cellular cytotoxicity in chronic SIV/SHIV infection. PLoS One 2013; 8: e56309.